Nautilus Biotechnology

Nautilus Biotechnology, Inc. operates as a life sciences company. The firm develops proteomics platform for analyzing and quantifying the human proteome. The company was founded by Sujal Patel and Parag Mallick in 2016 and is headquartered in Seattle, WA.

Earnings data Q1 2024

Nautilus reports Q1 loss, focuses on proteome access mission

Nautilus is making progress in its mission to provide ubiquitous access to the proteome, with a focus on accelerating target identification and drug development. The company's financial performance in Q1 2023 reflects conservative investment and a strong cash position. Challenges include the need for formal guidance on commercial launch pace and expanding supplier base for reagents and instruments.

Nautilus Biotechnology reports strong Q2 progress and plans mid-2024 platform launch

Nautilus Biotechnology's Q2 2023 performance reflects strong scientific and market progress, supported by robust R&D achievements and a healthy financial position. However, the company faces challenges in competitive positioning and customer interest, while also having significant opportunities in the upcoming platform launch and early access program.

Nautilus reports progress in R&D and aims to revolutionize proteomics

Nautilus showcased progress in R&D, financial management, and strategic partnerships. However, challenges related to expenses, product launch, and competition were acknowledged. The company's proactive approach to growth and upcoming product launch present opportunities for market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Nautilus Biotechnology, Inc. is a life sciences company, which engages in the development of a proteomics platform for analyzing and quantifying the human proteome. Its products include Proteome Analysis System, Reagent Kits, and Software and Analysis. The company was founded by Sujal Patel and Parag Mallick in 2016 and is headquartered in Seattle, WA.

Sujal Patel has been here before. He weathered the 2009 recession as CEO of Isilon Systems, coming out the other end to sell his company the next year for $2.25 billion.

Biotech industry leaders share cautious optimism for 2023 amid downturn and layoffs

Nautilus Biotechnology, Inc. (NASDAQ:NAUT ) Q3 2022 Earnings Conference Call November 1, 2022 8:30 AM ET Company Participants Sujal Patel - Co-Founder and CEO Parag Mallick - Co-Founder and Chief Scientist Anna Mowry - CFO Conference Call Participants Max Masucci - Cowen David Delahunt - Goldman Sachs Brandon Couillard - Jefferies Operator Ladies and gentlemen, thank you for standing by, and welcome to the Nautilus Q3 2022 Earnings Call. [Operator Instructions] I would now like to turn the call over to your host [Alex Khan], Investor Relations.

Nautilus Biotechnology, Inc. (NAUT) Q3 2022 Earnings Call Transcript

SEATTLE, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial results for the third quarter ended September 30, 2022.

Nautilus Biotechnology Reports Third Quarter 2022 Financial Results

Adobe

Starbucks

Loop Media Inc

United Natural Foods

Insiders buying stocks generally indicates a positive outlook from investors most in the know.

Insider Buying at Starbucks, Adobe and 3 Other Stocks

SEATTLE, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the company will be participating in the upcoming Capital One Spatial Biology & Proteomics Summit taking place virtually on Wednesday, September 28, 2022.

Nautilus Biotechnology to Participate in the Capital One Spatial Biology & Proteomics Summit

Representatives of company developing platform for comprehensively quantifying the proteome to provide HUPO leadership with input on technology and product innovation Representatives of company developing platform for comprehensively quantifying the proteome to provide HUPO leadership with input on technology and product innovation

Nautilus Biotechnology Joins Human Proteome Organization (HUPO) Industrial Advisory Board

SEATTLE, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the company will be participating in the upcoming Morgan Stanley Global Healthcare Conference in New York, NY.

Nautilus Biotechnology to Participate in the Morgan Stanley Global Healthcare Conference

Nautilus Biotechnology, Inc. (NASDAQ:NAUT ) Q2 2022 Earnings Conference Call August 2, 2022 8:30 AM ET Company Participants Sujal Patel - Founder and Chief Executive Officer Anna Mowry - Chief Financial Officer Parag Mallick - Founder and Chief Scientist Conference Call Participants Stephanie Yan - Cowen and Company, LLC Tejas Savant - Morgan Stanley David Delahunt - Goldman Sachs Operator Thank you for standing by, and welcome to the Nautilus Biotechnology Second Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode.

Nautilus Biotechnology, Inc. (NAUT) CEO Sujal Patel on Q2 2022 Results - Earnings Call Transcript

SEATTLE, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis, today reported financial results for the second quarter ended June 30, 2022.

Nautilus Biotechnology Reports Second Quarter 2022 Financial Results

SEATTLE, July 13, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced it will report financial results for the second quarter 2022 before market open on Tuesday, August 2nd, 2022.

Nautilus Biotechnology to Announce Second Quarter 2022 Financial Results on August 2, 2022

Nautilus Biotechnology, Inc. (NASDAQ:NAUT ) Q1 2022 Earnings Conference Call May 3, 2022 8:30 AM ET Company Participants Sujal Patel - Co-Founder & CEO Anna Mowry - CFO Parag Mallick - Co-Founder & Chief Scientific Officer Conference Call Participants Matt Kim - Jefferies Stephanie Yan - Cowen & Company Edmund Tu - Morgan Stanley David Delahunt - Goldman Sachs Operator Thank you for standing by, and welcome to the Nautilus Q1 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode.

Nautilus Biotechnology, Inc. (NAUT) CEO Sujal Patel on Q1 2022 Results - Earnings Call Transcript

SEATTLE, May 03, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis, today reported financial results for the first quarter ended March 31, 2022.

Nautilus Biotechnology Reports First Quarter 2022 Financial Results

SEATTLE, April 07, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced it will report financial results for the first quarter 2022 before market open on Tuesday, May 3rd, 2022.

Nautilus Biotechnology to Announce First Quarter 2022 Financial Results on May 3, 2022

• Co-founder and Chief Scientist Parag Mallick, Ph.D., to present lecture at Annual Congress of the European Proteomics Association (EuPA)  • Associate Director Greg Kapp, Ph.D., to present poster at American Association for Cancer Research (AACR) Annual Meeting

Nautilus Biotechnology to Present at EuPA and AACR Meetings

Schrödinger President of R&D, Therapeutics brings extensive leadership in commercializing breakthrough biotechnologies to company developing platform for comprehensively quantifying the proteome to enable fundamental advancements in biomedicine Schrödinger President of R&D, Therapeutics brings extensive leadership in commercializing breakthrough biotechnologies to company developing platform for comprehensively quantifying the proteome to enable fundamental advancements in biomedicine

Nautilus Biotechnology Appoints Karen Akinsanya, Ph.D., to Board of Directors

Nautilus Biotechnology, Inc. (NAUT) CEO Sujal Patel on Q4 2021 Results - Earnings Call Transcript

SEATTLE, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial results for the fourth quarter and fiscal year ended December 31, 2021.

Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2021 Financial Results

SEATTLE, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the company will be participating virtually in the upcoming 42nd Annual Cowen Health Care Conference.

Nautilus to Participate in the 42nd Annual Cowen Health Care Conference

Nautilus operates in the field of Proteomics, a $25 billion market, growing at 12% per year.

Nautilus Biotechnology: Recent Selloff Provides A Fantastic Entry Point

Ardelyx

Cumberland Pharma

Petros Pharmaceuticals

Are these on your list of penny stocks to buy this week? The post Penny Stocks To Buy This Week: 4 To Watch Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks To Buy This Week: 4 To Watch Right Now

Nautilus Biotechnology, Inc. (NAUT) CEO Sujal Patel on Q3 2021 Results - Earnings Call Transcript

Abcam

SEATTLE and CAMBRIDGE, England, Nov. 2, 2021 /PRNewswire/ -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or "Nautilus"), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, and Abcam (AIM:ABC; NASDAQ:ABCM), a global innovator in life sciences research tools, today announced a strategic development and supply partnership. The relationship leverages Abcam's industry-leading recombinant monoclonal antibody development technologies and expertise to enhance Nautilus' reagent research and development, and establishes a long-term supply relationship between the companies.

Nautilus and Abcam Announce Strategic Partnership to Accelerate Exploration of the Proteome

SEATTLE, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today reported financial results for the third quarter ended September 30, 2021.

Nautilus Biotechnology Reports Third Quarter 2021 Financial Results

SEATTLE, Oct. 11, 2021 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced it will report financial results for the third quarter of fiscal year 2021 before market open on Tuesday, November 2nd, 2021.

Nautilus Biotechnology to Announce Third Quarter of Fiscal Year 2021 Financial Results on November 2, 2021

SEATTLE, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the human proteome, today announced the company will be participating virtually in the upcoming Morgan Stanley Global Healthcare Conference.

News for Nautilus Biotechnology Stock (NAUT)